Cancers, Vol. 15, Pages 890: Lymph Node Involvement in Recurrent Serous Borderline Ovarian Tumors: Current Evidence, Controversies, and a Review of the Literature
Cancers, Vol. 15, Pages 890: Lymph Node Involvement in Recurrent Serous Borderline Ovarian Tumors: Current Evidence, Controversies, and a Review of the Literature
Cancers doi: 10.3390/cancers15030890
Authors:
Laureline Wetterwald
Apostolos Sarivalasis
Aikaterini Liapi
Patrice Mathevet
Chahin Achtari
Borderline ovarian tumors (BOTs) account for 10–20% of epithelial ovarian neoplasms. They are characterized by their lack of destructive stromal invasion. In comparison to invasive ovarian cancers, BOTs occur in younger patients and have better outcome. Serous borderline ovarian tumor (SBOT) represents the most common subtype of BOT. Complete surgical staging is the current standard management but fertility-sparing surgery is an option for SBOT patients who are at reproductive age. While most cases of SBOTs have an indolent course with favorable prognosis, late recurrence and malignant transformation can occur, usually in the form of low-grade serous carcinoma (LGSC). Thus, assessment of the recurrence risk is essential for the management of those patients. SBOTs can be associated with lymph node involvement (LNI) in up to 30% of patients who undergo lymph node dissection at diagnosis, and whether LNI affects prognosis is controversial. The present review suggests that recurrent SBOTs with LNI have poorer oncological outcomes and highlights the biases due to the scarcity of reports in the literature. Preventing SBOTs from recurring and becoming invasi...
Source: Cancers - Category: Cancer & Oncology Authors: Laureline Wetterwald Apostolos Sarivalasis Aikaterini Liapi Patrice Mathevet Chahin Achtari Tags: Review Source Type: research
More News: Borderline Serous Tumor | Borderline Tumor | Cancer | Cancer & Oncology | Carcinoma | Epithelial Cancer | Ovarian Cancer | Ovaries | Reproduction Medicine | Serous Carcinoma